

# Submission Confirmation for AMSU-D-22-00004R1

Inbox

**Annals of Medicine and Surgery** <em@editorialmanager.com> Jan 30, 2022,  
6:58 AM

to me

Ms. Ref. No.: AMSU-D-22-00004R1  
Title: The Role of MLC901 in Reducing VEGF as  
a Vascular Permeability Marker in Rats with Spinal Cord Injury  
Annals of Medicine and Surgery

Dear Dr Rosyidi,

This message is to acknowledge that we have received your revised manuscript for reconsideration for publication in Annals of Medicine and Surgery.

You may check the status of your manuscript by logging into the Editorial Manager as an author at <https://www.editorialmanager.com/amsu/>.

Thank you for submitting your work to Annals of Medicine and Surgery.

Kind regards,

Editorial Manager  
Annals of Medicine and Surgery

\*\*\*\*\*

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

**Editor handles AMSU-D-22-00004R1**

Inbox



**Annals of Medicine and Surgery** <em@editorialmanager.com>

Wed, Feb 2,  
2022, 6:09 AM

to me

Ms. Ref. No.: AMSU-D-22-00004R1  
Title: The Role of MLC901 in Reducing VEGF as  
a Vascular Permeability Marker in Rats with Spinal Cord Injury  
Annals of Medicine and Surgery

Dear Dr Rosyidi,

Your submission "The Role of MLC901 in Reducing VEGF as  
a Vascular Permeability Marker in Rats with Spinal Cord Injury" will be handled by  
Editor in Chief Riaz Agha.

You may check on the progress of your paper by logging on to the Editorial Manager  
as an author.

Thank you for submitting your work to this journal.

Kind regards,

Editorial Manager  
Annals of Medicine and Surgery

\*\*\*\*\*

For further assistance, please visit our customer support site  
at <http://help.elsevier.com/app/answers/list/p/7923>

Here you can search for solutions on a range of topics, find answers to frequently  
asked questions and learn more about EM via interactive tutorials. You will also find  
our 24/7 support contact details should you need any further assistance from one of  
our customer support representatives.

---

In compliance with data protection regulations, you may request that we remove your  
personal registration details at any time. (Use the following  
URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the  
publication office if you have any questions.

Reviewers' and Managing Editor comments:

Managing Editor

Please can you make the following changes/checks:

Reviewer 1

1. The subject is very limited only ten rats, if you think it is hard to do the treatment to make a spinal injury in rats you should change the animals. you can use like rabbits, and make a bigger number of subjects. so we can not make any conclusions to this such this limited subjects, we know from the beginning VEGF kind like antiapoptotic effects on endothelial cell and increase vascular permeability, using MLC 901 to maintain the level of VEGF is a very good idea, but it should have a basic good research with the bigger population subjects.

Reviewer 3

1. Spinal cord injury is a serious disease, and its treatment has always been a hot issue.
2. It is suggested that the background part of the abstract of this paper be completely revised, which is seriously inconsistent with the title
3. What is the sample size of this paper? In addition, I don't think the results of this paper can support the conclusion. It is suggested that the author supplement the experimental content and carefully proofread the content of the article
4. The author did not carefully check the article according to the guide The ARRIVE guidelines 2.0. Please check it carefully
5. The key words neuroprotective, neurogenesis in the article seem to be inconsistent with the article

Answer of Reviewers' and Managing Editor comments:

Managing Editor

Please can you make the following changes/checks:

Reviewer 1

1. The subject is very limited only ten rats, if you think it is hard to do the treatment to make a spinal injury in rats you should change the animals. you can use like rabbits, and make a bigger number of subjects. so we can not make any conclusions to this such this limited subjects, we know from the beginning VEGF kind like antiapoptotic effects on endothelial cell and increase vascular permeability, using MLC 901 to maintain the level of VEGF is a very good idea, but it should have a basic good research with the bigger population subjects.

Answer :

Thanks Sir. The sample size according to the WHO criteria in the Research Guideline for Evaluating The Safety and Efficacy of Herbal Medicines, which is a minimum number of 5 individuals per group with a reserve for anticipating drop out of 10% (1 head). it will be very considered for the further experiment to use bigger

number of samples size.

Reviewer 3

1. Spinal cord injury is a serious disease, and its treatment has always been a hot issue.
2. It is suggested that the background part of the abstract of this paper be completely revised, which is seriously inconsistent with the title
3. What is the sample size of this paper? In addition, I don't think the results of this paper can support the conclusion. It is suggested that the author supplement the experimental content and carefully proofread the content of the article
4. The author did not carefully check the article according to the guide The ARRIVE guidelines 2.0. Please check it carefully
5. The key words neuroprotective, neurogenesis in the article seem to be inconsistent with the article

Answer :

1. Thanks Sir.
2. Thanks Sir. I've changed the background part of the abstract.
3. Thanks Sir. In this true experimental research, we used Ten Sprague Dawley rats with spinal cord injury were randomly divided into two groups: (1) with MLC 901 administration, and (2) without MLC 901 administration (placebo).
4. Thanks Sir. It has been checked carefully and has been corrected according to the guide of ARRIVE Guideline 2.0 and I've added it to the manuscript.
5. Thanks Sir. I've changed the keywords neuroprotective and neurogenesis.

## our Submission

Inbox



**Annals of Medicine and Surgery** <em@editorialmanager.com>

Fri, Feb 4,  
2022, 6:36 AM

to me

Ms. Ref. No.: AMSU-D-22-00004R1

Title: The Role of MLC901 in Reducing VEGF as  
a Vascular Permeability Marker in Rats with Spinal Cord Injury  
Annals of Medicine and Surgery

Dear Dr Rosyidi,

I am pleased to inform you that your paper "The Role of MLC901 in Reducing VEGF as a Vascular Permeability Marker in Rats with Spinal Cord Injury" has been accepted for publication in Annals of Medicine and Surgery.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders. In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

Learn about publishing Open Access in this journal at <http://www.elsevier.com/journals/Annals-of-Medicine-and-Surgery/2049-0801/open-access-journal>.

Your manuscript will be published online in raw form 4 days from this acceptance.

We appreciate and value your contribution to Annals of Medicine and Surgery. We regularly invite authors of recently published manuscript to participate in the peer review process. If you were not already part of the journal's reviewer pool, you have now been added to it. We look forward to your continued participation in our journal, and we hope you will consider us again for future submissions.

Yours sincerely,

Dr Riaz Agha  
Editorial Office  
Annals of Medicine and Surgery

## IMPORTANT – Track your article [AMSU\_103344]

Inbox



Elsevier - Article Status <Article\_Status@elsevier.com>

Fri, Feb 4,  
2022, 8:05 AM

to me

**ELSEVIER**

Track your article!

Dear Dr Rosyidi,

Your



article *The Role of MLC901 in Reducing VEGF as a Vascular Permeability Marker in Rats with SpinalCord Injury* will be published in Annals of Medicine and Surgery.

To track the status of your article throughout the publication process, please use our article tracking service:

<https://authors.elsevier.com/tracking/article/details.do?aid=103344&jid=A MSU&surname=Rosyidi>

For help with article tracking go to [Elsevier Support](#).

We are committed to publishing your article as quickly as possible. We will therefore send you an alert of each next step in the production process where your involvement is required.

Once the expected dispatch date of your proofs is available, you will be automatically alerted by e-mail.

Yours sincerely,  
Elsevier Researcher Support

**Have questions or need assistance?**

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | Privacy Policy <http://www.elsevier.com/privacypolicy>  
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom,  
Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your  
inbox (not bulk or junk folders), please add [Article\\_Status@elsevier.com](mailto:Article_Status@elsevier.com) to your address book or safe  
senders list.

## IMPORTANT PLEASE TAKE ACTION, Production has begun on your article [AMSU\_103344] in Annals of Medicine and Surgery

Inbox

**A.Achuthan@elsevier.com**

Fri, Feb 4, 2022,  
10:11 PM

to me

-----  
Our reference: AMSU 103344  
Article reference: AMSU\_AMSU-D-22-00004  
Article title: The role of MLC901 in reducing VEGF as  
a vascular permeability marker in rats with spinal cord injury  
To be published in: Annals of Medicine and Surgery

-----  
Dear Dr Rosyidi,

Congratulations on your accepted paper! Thank you for choosing to publish in  
Annals of Medicine and Surgery. Please read this e-mail carefully as it contains  
important information.

### FINALIZE PUBLISHING YOUR ARTICLE:

We work hard to publish our authors' articles online as quickly as possible, so we're  
happy to report that processing of your manuscript has already begun. To ensure  
that we publish your article in accordance with your wishes, please now complete  
these forms

[http://authors.elsevier.com/authorforms/AMSU103344/170f47955a00a687251787cc  
2728994b](http://authors.elsevier.com/authorforms/AMSU103344/170f47955a00a687251787cc2728994b)

If this link does not work, please copy the entire URL (noting that it may run on to a  
second line in this message) into your browser. You should log in with your Elsevier  
Profile credentials, which you may have already created when submitting your  
article.

### CHECK YOUR CONTACT DETAILS:

Please check that your details listed below are correct so we can contact you if

needed:

Dr Rohadi Muhammad Rosyidi  
Medical Faculty of Mataram University  
Departement of Neurosurgery  
Mataram  
Indonesia  
Phone: not available  
Fax: not available  
E-mail: [rha.ns2010@gmail.com](mailto:rha.ns2010@gmail.com)

YOUR REFERENCE NUMBER:

To help us provide you with the best service, please make a note of your article's reference number AMSU 103344 and quote it in all of your messages to us.

If you wish to find out more about the next steps in the publication process and for further help and / or information please visit our Author hub, link below:  
[https://service.elsevier.com/app/answers/detail/a\\_id/34514/c/10532/supporthub/publishing/](https://service.elsevier.com/app/answers/detail/a_id/34514/c/10532/supporthub/publishing/)

Thank you for your cooperation.

Kind regards,

A Achuthan  
Data Administrator  
Elsevier  
E-Mail: [A.Achuthan@elsevier.com](mailto:A.Achuthan@elsevier.com)

-----  
HAVE QUESTIONS OR NEED ASSISTANCE?

For further assistance, Please feel free to talk to our Researcher support team via 24/7 live chat and e-mail or avail our phone support for 24/7. Please visit our Elsevier support Center where you can search for solutions on a range of topics and find answers to frequently asked questions, Get started here:

<http://service.elsevier.com/app/home/supporthub/publishing>

-----  
Copyright © 2015 Elsevier B.V. | Privacy  
Policy <http://www.elsevier.com/privacypolicy>  
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB,  
United Kingdom, Registration No. 1982084